A rare mutation in the GDF2 gene was identified in two siblings, a boy and a girl, with pulmonary arterial hypertension (PAH), according to a recent case report. The mutation, which each child inherited in both gene copies, resulted in a lack of the bone morphogenetic protein (BMP) 9 in the…
News
Cigarette smoking in men newly diagnosed with pulmonary arterial hypertension (PAH) was associated with a faster time to in-patient hospitalization and death after diagnosis, according to an analysis of the REVEAL study in the U.S. More men smoked than women, and ever-smoking status (someone who has been a cigarette…
The experimental therapy HS135 improved heart function and the remodeling of lung blood vessels in a rat model of pulmonary hypertension (PH). That’s according to data reported by the therapy’s developer, 35Pharma, at the 2022 American Heart Association Scientific Sessions (AHA 2022), held earlier this month in Chicago…
An inhaled form of APN01 (alunacedase alfa), APEIRON Respiratory Therapies (AResT)’s investigational therapy for certain lung diseases, was safe and well-tolerated in healthy people, according to data from a Phase 1 clinical trial. “In addition to meeting all primary [goals] regarding the safety and tolerability of APN01 via a new…
Virginia Venture Partners — Virginia Innovation Partnership Corporation (VIPC)’s equity investment program — is investing in OxiWear and its modern ear-wearable device that’s designed to continuously monitor blood oxygen levels in people with pulmonary hypertension (PH). The OxiWear device alerts the user through a phone app when there’s…
A short treatment with Remodulin (injectable treprostinil) before initiating Orenitram (oral treprostinil) allows pulmonary arterial hypertension (PAH) patients to achieve double the normal doses of the oral therapy without increasing side effects. These are the findings of a preliminary analysis of top-line data from the Phase…
Patients, caregivers, family members, and friends are set to mark Pulmonary Hypertension Awareness Month, observed each November to call attention to the complex, chronic, progressive disorder. Awareness and education are vital to heightening the recognition, diagnosis, understanding, and management of pulmonary hypertension (PH), a disease associated with high blood…
Children with episodes of fainting due to pulmonary arterial hypertension (PAH) who respond well to a vasodilator given in a challenge test are likely to have better long-term outcomes than those who respond poorly, a long-term records study suggests. A vasodilator challenge is a test to measure blood pressure in…
Premature newborns who are treated for eye problems with anti-VEGF therapies may be at increased risk of developing pulmonary hypertension, a new study suggests. “Future studies evaluating the safety of anti-VEGF therapy should include pulmonary hypertension as a key clinical outcome. This is especially important as anti-VEGF treatment usage…
The U.S. Food and Drug Administration (FDA) granted breakthrough device designation to the CorVista System, a point-of-care diagnostic tool that aims to use non-invasive tests and machine learning to help diagnose pulmonary hypertension and other cardiovascular disorders. The designation gives CorVista Health, the system’s developer, certain benefits aimed…
People with pulmonary arterial hypertension (PAH) are at a higher risk of acute heart failure when admitted to the hospital for sepsis or septic shock than are patients without PAH, a U.S. study found. Sepsis — the body’s severe response to infection — in PAH patients, however, was not…
Treatment with Adcirca (tadalafil) or Revatio (sildenafil) may help patients who develop pulmonary hypertension secondary to an interstitial lung disease to live longer, according to a new study from the U.K. “Patients treated with [these therapies] survived longer than untreated patients,” the researchers wrote, noting a median survival of…
